Guest Post: Colorcon A Case Study – Part 1

May 7, 2017

Impact of Moisture Barrier Film Coating on Stability of Amoxicillin/Clavulanic Acid Tablets

Product stability is affected by all elements of solid dosage development and manufacturing including core formulation, excipient choice, manufacturing conditions, packaging and end use storage conditions. Film coating can protect tablets from environmental factors such as moisture, light, or oxygen while presenting the opportunity to improve product identification and patient compliance.

Impact of Moisture Barrier Film Coating on Stability of Amoxicillin/Clavulanic Acid Tablets

Amoxicillin and clavulanic acid are combined to produce an antibiotic with an increased spectrum of action against some amoxicillin-resistant bacteria. Due to the high sensitivity of clavulanic acid to moisture, this combination was selected to investigate the moisture protection properties of Opadry amb II. This antibiotic combination product is typically coated with an hypromellose (HPMC) based film coating.

Part I: In-Use Product Integrity

The in-use stability of an uncoated amoxicillin / clavulanic acid dosage form was compared against similar tablets coated using a standard HPMC- based film coating and Opadry amb II aqueous moisture barrier coating.
Uncoated and coated tablets were removed from their primary packaging and transferred to a typical consumer-use tablet organizer and stored for the prescribed ten-day regimen at 25°C/60% RH. On each day, tablets were removed from the organizer and assayed according to the USP method for each drug component.
Results showed significant degradation of the clavulanic acid for uncoated and HPMC-coated tablets. At the end of the ten-day dose regimen, amoxicillin levels were shown to have decreased by 20% of the initial amount, but still within the USP assay specification of 90-120%. In contrast, clavulanic acid levels were totally depleted at the end of ten days; however, tablets coated with Opadry amb II maintained acceptable levels.

Application of the Opadry amb II coating resulted in improved tablet stability, even when removed from the primary packaging.

Colorcon, from Core to Coating, Your Supplier of Choice

At Colorcon, we formulate, we innovate — and we focus our coatings and excipients exclusively for pharmaceutical and nutritional oral solid dosages.
That’s why, when you set out to select the right coating or excipient for your formulation, be sure to partner with the leading company that brings you innovative products plus specialized technical support when and where you need it.

Be confident with your choice

Author: Colorcon
Website: www.colorcon.com


Read More

Ethnic Business Awards Foundation
Read More >
Innovation Delivering exceptional results!
Read More >
Vitex is proud to share the honour bestowed upon it’s Chairman
Read More >
Mr Elie Chami, Chairman - A Pioneer!
Read More >
“A Leader is one who knows the way, goes the way and shows the way.” (John C Maxwell)
Read More >
Vitex hosts Minister of Public Health for Lebanon, Dr Firass Abiad
Read More >
Vitex named HRD Australia 5-Star Employer of Choice 2024
Read More >
Sue Irvine, Chief Human Resource Officer, named HRD’s Hot List 2024 Winner
Read More >
CEO of Vitex Pharmaceuticals, Dr Aniss Chami is proud to be appointed as a career ambassador for Careers NSW.
Read More >